Octapharma Ag
Octapharma Receives Orphan Drug Exclusivity Approval for wilate - a Replacement Therapy Developed Specifically for von Willebrand Disease
Published in Medical Letter on the CDC and FDA, January 31st, 2010
Octapharma AG, one of the largest manufacturers of plasma products in the world, announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA). The approval was granted for the use of wilate® for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as in patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.
The FDA's approval and granting of orphan drug exclusivity of wilate® marks the entrance of Octapharma USA into the U.S. blood coagulation...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- American Association for Cancer Research
Gene testing identifies lung cancer patients who benefit from ALK-inhibitor drug - New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Reducing dosage of Parkinson's drugs can cause symptoms similar to those of cocaine withdrawal - Absorption Systems
Study Shows the Unique Power of Absorption Systems' CellPort Technologies(TM) - Blue Spoon Consulting Group, LLC
Blue Spoon Publishes Industry Strategy for FDA's Sentinel Initiative - Cervical Intraepithelial Neoplasia
Studies from S. Tiews and co-researchers update current data on cervical intraepithelial neoplasia - Drug Development
Studies from J.J.P. Schimmel et al add new findings in the area of drug development - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
